The bill declares that any FDA approval for mifepristone with an indication for terminating intrauterine pregnancy is ‘‘deemed withdrawn’’ (effective 14 days after enactment), treats introduction into interstate commerce of that drug as a violation of the Federal Food, Drug, and Cosmetic Act, and makes certain labeling about termination use misbranding. Separately, it creates a new federal tort that allows individuals who suffer bodily injury or harm to mental health that is attributable in whole or in part to use of the covered medication to sue the manufacturer for compensatory and punitive damages and recover attorneys’ fees.
Why this matters: the measure bypasses ordinary FDA administrative processes by using statute to remove an approved indication, converts distribution across state lines into a FDCA violation, and imposes a broad private-liability regime on manufacturers. That combination affects manufacturers, pharmacies, telemedicine and mail-order distribution, clinicians who prescribe or dispense the drug, and the FDA’s enforcement priorities — and it raises immediate questions about causation standards, labeling, and the interplay between federal statutory action and existing state remedies.
At a Glance
What It Does
The bill statutorily ‘‘deems’’ FDA approval of mifepristone for terminating intrauterine pregnancy withdrawn 14 days after enactment, makes interstate introduction of the drug a violation of the FDCA, and declares labeling that indicates termination use to be misbranding. It also establishes a federal private right of action against manufacturers for bodily injury or harm to mental health tied to use of the covered medication, allowing compensatory and punitive damages plus attorneys’ fees.
Who It Affects
Manufacturers of mifepristone (and any product relying on it as a reference drug), pharmacies and distributors that ship or fill prescriptions across state lines, telemedicine providers and mail-order services that facilitate access, clinicians who prescribe or counsel on medication abortion, and the FDA and state regulators who enforce FDCA violations.
Why It Matters
By removing an FDA indication by statute rather than agency action and layering on federal tort liability, the bill shifts both regulatory control and litigation risk from the FDA and medical malpractice regimes to statutory enforcement and private suits — potentially cutting off national distribution paths and increasing liability exposure for manufacturers and downstream suppliers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill works in two parallel ways. First, it treats any FDA approval of mifepristone for the termination of intrauterine pregnancy as if withdrawn under the FDCA 14 days after enactment.
Once that statutory withdrawal takes effect, introducing the drug into interstate commerce becomes a violation tied to FDCA provisions cited in the bill. The bill also defines as misbranded any mifepristone labeling that says the drug may be used to terminate pregnancy or that it may be used with another drug for that purpose.
Second, the bill creates a federal private right of action targeted at manufacturers. It defines the covered medication narrowly as mifepristone approved for termination and the covered entity as a person that manufactures that medication for introduction into interstate commerce.
An individual who alleges bodily injury or harm to mental health ‘‘attributable, in whole or in part’’ to their use of the covered medication may sue in state or federal court for compensatory damages, punitive damages, and attorneys’ fees and costs. The tort provision takes effect 90 days after enactment.The statute explicitly says it does not preempt State laws that offer additional remedies, leaving parallel state litigation routes intact.
It also includes a short rule of construction preserving a specified provision of title 18 (section 1461), though it does not elaborate on how that interacts with the rest of the bill. Practically, the combined effect is to turn statutory authority into an immediate tool for limiting distribution across state lines while creating a new federal litigation path for alleged harms from the drug.
The Five Things You Need to Know
Section 2 deems any FDA approval of mifepristone for termination of intrauterine pregnancy withdrawn 14 days after enactment.
The bill treats introduction or delivery for introduction into interstate commerce of the withdrawn drug as a violation of the FDCA under the sections cited (301(d) and 304).
Mifepristone will be ‘‘misbranded’’ under this Act if its labeling states it may be used to terminate pregnancy or may be used in conjunction with another drug for that purpose.
Section 3 defines a covered medication (mifepristone with the termination indication) and a covered entity (manufacturer) and allows individuals to sue manufacturers for bodily injury or harm to mental health attributable in whole or in part to use, seeking compensatory and punitive damages plus attorneys’ fees.
The federal tort provision becomes effective 90 days after enactment, and the Act includes a rule preserving section 1461 of title 18, U.S. Code.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s short name, ‘‘Safeguarding Women from Chemical Abortion Act.’
Deemed withdrawal of mifepristone approval and labeling/misbranding rules
Deems approval under FDCA section 505 for mifepristone’s indication to terminate intrauterine pregnancy to be withdrawn 14 days after enactment and treats distribution into interstate commerce of that product as a violation of the FDCA. It also declares mifepristone misbranded if labeling indicates it may be used to terminate pregnancy or used with another drug for termination. Mechanically, this provision attempts to apply FDCA enforcement tools to halt distribution and sets a statutory labeling rule rather than relying on agency action.
Federal tort: definitions, liability, remedies, and construction
Creates a new federal cause of action specifically aimed at manufacturers: a covered entity is any person that manufactures the covered medication (mifepristone as approved for termination) for interstate commerce. Individuals who suffer bodily injury or harm to mental health that is attributable in whole or in part to their use of the covered medication may sue in state or federal court. Available relief includes compensatory and punitive damages and attorneys’ fees. The section also clarifies that it does not preempt state laws that provide other remedies, and it becomes effective 90 days after enactment.
Rule of construction
States that nothing in the Act shall be construed to affect section 1461 of title 18, U.S. Code. The bill does not explain the operational relationship between that criminal statute and the FDCA violations and civil liability it imposes elsewhere in the Act, leaving a gap for implementers and courts to resolve.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals who allege injury from mifepristone: The Act creates a clear federal litigation path to seek compensatory and punitive damages and recover attorneys’ fees against manufacturers.
- State governments and private plaintiffs pursuing restrictions on chemical abortion: By making interstate distribution a statutory FDCA violation and labeling misbranding, states or private enforcers may have additional leverage to curtail access.
- Plaintiff-side law firms and public-interest groups opposing chemical abortion: New statutory causes of action and a non-preemption clause expand potential claims and remedies, likely increasing litigation opportunities for those representing plaintiffs.
- Local providers in jurisdictions that already restrict medication abortion: The statutory withdrawal and commerce prohibition could align federal law with existing state bans, simplifying enforcement for states that limit or prohibit chemical abortion.
Who Bears the Cost
- Manufacturers of mifepristone and any related generics: They face immediate market loss for the termination indication and exposure to new federal tort claims, including punitive damages and attorneys’ fees.
- Pharmacies, telemedicine and mail-order distributors: Firms that ship or dispense mifepristone across state lines could face FDCA violation exposure and downstream liability risk if the product is treated as withdrawn or misbranded.
- Clinicians and health systems providing medication abortion: Reduced availability of the drug and increased legal uncertainty could disrupt care pathways and require alternative clinical and legal workflows.
- The FDA and federal enforcement apparatus: The agency and DOJ could see increased enforcement demands and litigation challenging whether Congress can statutorily withdraw an approval and how to apply FDCA remedies.
- Insurers and payers: Reduced access or shifts to surgical alternatives may raise costs and change coverage patterns if medication abortion pathways are curtailed.
Key Issues
The Core Tension
The central dilemma: the bill aims to advance accountability and restrict access to a drug it treats as harmful versus the broader public-health and administrative-law consequences of removing an FDA-approved indication by statute — a step that substitutes legislative fiat for agency science-based review and that may sharply curtail access, disrupt supply chains, and impose expansive litigation risk on manufacturers and downstream healthcare actors.
The bill creates immediate legal and implementation puzzles. Statutorily ‘‘deeming’’ an FDA approval withdrawn bypasses the agency’s ordinary revocation, labeling, and postmarket processes, which invites litigation over statutory authority, separation of powers, and administrative-procedure limits.
Courts will confront whether Congress can single out a specific approved indication and the consequences for related regulatory frameworks (for example, reference-product status used by generic applicants). The statutory route also raises practical enforcement questions: treating interstate introduction as an FDCA violation could criminalize previously lawful distribution channels and create large compliance burdens for distributors and pharmacies.
The tort provision is broad in scope but thin on procedural detail. It defines harm to include ‘‘mental health’’ and permits liability for harms ‘‘attributable, in whole or in part,’’ language that lowers traditional causation thresholds and could multiply suits with contested medical causation.
At the same time, the Act preserves state-law remedies, which enables forum shopping and parallel litigation across jurisdictions. The lack of statutory safe-harbors, pre-litigation notice requirements, or scientifically tailored causation standards increases uncertainty for manufacturers and may chill research, manufacturing, and distribution of related products.
Finally, the bill’s brief carve-out preserving 18 U.S.C. 1461 is unexplained and creates another interpretive layer for courts deciding how criminal statutes intersect with the new FDCA violations and civil liability the Act establishes.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.